Paediatric studies
Dr. Paul Heath
These
studies are currently supported by clinical paediatric research fellows and paediatric nurses based in the Vaccine Institute
Vaccines
New Vaccines in healthy children
- A multicentre follow on study of the 13-valent pneumococcal conjugate vaccine evaluating a booster dose in healthy pre- school children. Funded by Pfizer Vaccines.
- A multicentre follow on study of the Meningococcal B vaccine evaluating a booster dose in healthy toddlers. Funded by Novartis Vaccines.
- A multicentre study of a novel live attenuated Respiratory Syncitial Virus (RSV) - parainfluenza virus GM vaccine in healthy infants. Funded by MedImmune.
New vaccines in “at risk children”
PCV-13 (Prevnar13) study in Sickle cell disease (SCD) patients aged 6 years-18 years.
A Multicentre, Phase 3, open label, single-arm trial evaluating the safety, tolerability and Immunogenicity of 13-valent Pneumococcal conjugate vaccine in children with sickle cell disease previously immunised with 23-valent Pneumococcal polysaccharide vaccine.
Pandemrix (GSK), H1H1 pandemic vaccine in HIV-infected children and children with malignancies aged 6 – 18 years.
In conjunction with the HPA CFI we are conducting a service evaluation of H1N1 vaccine (Pandemrix) in these high risk children.
2 doses of the vaccine are given 3 weeks apart with 2 blood tests; before 1st dose and 3 weeks post 2nd dose
Antibiotic Studies
NeoMero2
A European multicenter network to evaluate pharmacokinetics, safety and efficacy of meropenem in neonatal meningitis. Funded by the EC FP7 program.
Epidemiological Studies
NeonIN
We coordinate a multicentre neonatal infection surveillance network, currently with 18 neonatal units around England.
NeoMen
St. George’s, University of London, in conjunction with the British Paediatric Surveillance Unit, Health Protection Agency, Health Protection Scotland, Irish Meningococcal and Meningitis Reference Laboratory. Bacterial meningitis in infants less than 90 days of age. This study aims to conduct a comprehensive study of bacterial meningitis in infants less than 90 days of age in the UK and Ireland, to define the optimal management of meningitis in this age group, to describe the current management with reference to this and thus to define opportunities for improving the outcome.